-
1
-
-
11144354339
-
Prevalence of agerelated macular degeneration in the United States
-
Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
-
(2004)
Arch Ophthalmol.
, vol.122
, pp. 564-572
-
-
Friedman, D.S.1
O'Colmain, B.J.2
Munoz, B.3
-
2
-
-
11144239923
-
Pegaptanib for neovascular age-related macular degeneration
-
Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
-
(2004)
N Engl J Med.
, vol.351
, pp. 2805-2816
-
-
Gragoudas, E.S.1
Adamis, A.P.2
Cunningham Jr., E.T.3
Feinsod, M.4
Guyer, D.R.5
-
3
-
-
33749451356
-
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
-
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
-
(2006)
N Engl J Med.
, vol.355
, pp. 1432-1444
-
-
Brown, D.M.1
Kaiser, P.K.2
Michels, M.3
-
4
-
-
33749445317
-
Ranibizumab for neovascular age-related macular degeneration
-
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
-
(2006)
N Engl J Med.
, vol.355
, pp. 1419-1431
-
-
Rosenfeld, P.J.1
Brown, D.M.2
Heier, J.S.3
-
5
-
-
33750305221
-
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled openlabel clinical study
-
Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled openlabel clinical study. Ophthalmology. 2006;113:2002, e2001-2012.
-
(2006)
Ophthalmology.
, vol.113
-
-
Moshfeghi, A.A.1
Rosenfeld, P.J.2
Puliafito, C.A.3
-
6
-
-
20144372969
-
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study
-
Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047.
-
(2005)
Ophthalmology.
, vol.112
, pp. 1035-1047
-
-
Michels, S.1
Rosenfeld, P.J.2
Puliafito, C.A.3
Marcus, E.N.4
Venkatraman, A.S.5
-
7
-
-
33750296920
-
The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide
-
Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-1349.
-
(2006)
Br J Ophthalmol.
, vol.90
, pp. 1344-1349
-
-
Fung, A.E.1
Rosenfeld, P.J.2
Reichel, E.3
-
8
-
-
33745386921
-
Intravitreal Avastin: The low cost alternative to lucentis?
-
Rosenfeld PJ. Intravitreal Avastin: the low cost alternative to lucentis? Am J Ophthalmol. 2006;142:141-143.
-
(2006)
Am J Ophthalmol.
, vol.142
, pp. 141-143
-
-
Rosenfeld, P.J.1
-
10
-
-
0029097631
-
Human scleral permeability: Effects of age, cryotherapy, transscleral diode laser, and surgical thinning
-
Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36:1893-1903.
-
(1995)
Invest Ophthalmol Vis Sci.
, vol.36
, pp. 1893-1903
-
-
Olsen, T.W.1
Edelhauser, H.F.2
Lim, J.I.3
Geroski, D.H.4
-
11
-
-
13944264268
-
Permeability of retinal pigment epithelium: Effects of permeant molecular weight and lipophilicity
-
Pitkanen L, Ranta VP, Moilanen H, Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci. 2005;46:641-646.
-
(2005)
Invest Ophthalmol Vis Sci.
, vol.46
, pp. 641-646
-
-
Pitkanen, L.1
Ranta, V.P.2
Moilanen, H.3
Urtti, A.4
-
12
-
-
0036241133
-
Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye
-
Einmahl S, Savoldelli M, D'Hermies F, Tabatabay C, Gurny R, Behar-Cohen F. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest Ophthalmol Vis Sci. 2002;43:1533-1539.
-
(2002)
Invest Ophthalmol Vis Sci.
, vol.43
, pp. 1533-1539
-
-
Einmahl, S.1
Savoldelli, M.2
D'Hermies, F.3
Tabatabay, C.4
Gurny, R.5
Behar-Cohen, F.6
-
13
-
-
33750086968
-
Cannulation of the suprachoroidal space: A novel drug delivery methodology to the posterior segment
-
Olsen TW, Feng X, Wabner K, et al. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am J Ophthalmol. 2006;142:777-787.
-
(2006)
Am J Ophthalmol.
, vol.142
, pp. 777-787
-
-
Olsen, T.W.1
Feng, X.2
Wabner, K.3
-
14
-
-
65249085544
-
Canaloplasty: Circumferential viscodilation and tensioning of Schlemm canal using a flexible microcatheter for the treatment of open-angle glaucoma in adults: Two-year interim clinical study results
-
Lewis RA, von Wolff K, Tetz M, et al. Canaloplasty: circumferential viscodilation and tensioning of Schlemm canal using a flexible microcatheter for the treatment of open-angle glaucoma in adults: two-year interim clinical study results. J Cataract Refract Surg. 2009;35:814-824.
-
(2009)
J Cataract Refract Surg.
, vol.35
, pp. 814-824
-
-
Lewis, R.A.1
von Wolff, K.2
Tetz, M.3
-
15
-
-
78649529307
-
Barrier analysis of periocular drug delivery to the posterior segment
-
Ranta VP, Mannermaa E, Lummepuro K, et al. Barrier analysis of periocular drug delivery to the posterior segment. J Control Release. 2010;148:42-48
-
(2010)
J Control Release
, vol.148
, pp. 42-48
-
-
Ranta, V.P.1
Mannermaa, E.2
Lummepuro, K.3
-
16
-
-
0000510983
-
The drainage of albumin from the uvea
-
Bill A. The drainage of albumin from the uvea. Exp Eye Res. 1964;3:179-187.
-
(1964)
Exp Eye Res.
, vol.3
, pp. 179-187
-
-
Bill, A.1
-
17
-
-
0001364939
-
Movement of albumin and dextran through the sclera
-
Bill A. Movement of albumin and dextran through the sclera. Arch Ophthalmol. 1965;74:248-252.
-
(1965)
Arch Ophthalmol.
, vol.74
, pp. 248-252
-
-
Bill, A.1
-
19
-
-
77953300103
-
Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: A retrospective cohort study
-
Johnson D, Hollands H, Hollands S, Sharma S. Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study. Can J Ophthalmol. 2010;45:239-242.
-
(2010)
Can J Ophthalmol.
, vol.45
, pp. 239-242
-
-
Johnson, D.1
Hollands, H.2
Hollands, S.3
Sharma, S.4
-
20
-
-
64849085452
-
Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)
-
Georgopoulos M, Polak K, Prager F, Prunte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol. 2009;93:457-462.
-
(2009)
Br J Ophthalmol.
, vol.93
, pp. 457-462
-
-
Georgopoulos, M.1
Polak, K.2
Prager, F.3
Prunte, C.4
Schmidt-Erfurth, U.5
|